Strategic partnerships NorthStar is actively expanding its ecosystem through multi-year collaborations and strategic partnerships with organizations like Zeno Power, Low Institute for Therapeutics, QSA Global, and BIOEMTECH, indicating strong sales opportunities in CDMO services, actinium-225 supply, and radiopharmaceutical development collaborations.

Expanded manufacturing footprint The recent Beloit facility expansion and 52,000 square-foot advanced manufacturing center position NorthStar to scale production of Cu-67 and Ac-225, creating upsell potential for contract manufacturing, process development, and supply-chain services for growth-stage and mature radiopharmaceutical programs.

Leadership in niche isotopes As the first commercial-scale producer of no-carrier-added Ac-225 and a Cu-67 producer, NorthStar holds differentiated capability in high-demand radiopharmaceutical isotopes, suggesting opportunities to up-sell global supply agreements, custom isotope sourcing, and exclusive manufacturing arrangements.

Commercialization focus With a CDMO unit and a proven management team serving biopharma partners to rapidly advance programs, there is potential for expanded service offerings in development support, regulatory-ready manufacturing, and early commercial phase partnerships to accelerate market entry.

Market presence signals Regular engagement through major conferences and visible leadership hires such as a Chief Commercial Officer indicate a proactive go-to-market strategy and readiness to engage in enterprise deals, channel partnerships, and long-term supply contracts with pharma and research institutions.